Macrogenics (FRA:M55) Tariff Resilience Score: 7/10 (As of Jul. 09, 2026)


FRA:M55 Macrogenics Inc FRA:M55
47 GF Score
Price €4.12
GF Value €3.59
Valuation Modestly Overvalued
! 8 Warning Signs
View Full Analysis

What is Macrogenics Tariff Resilience Score?

Macrogenics FRA:M55 +4.04% 47 Tariff Resilience Score is 7 as of Jul. 09, 2026. GuruFocus rates FRA:M55 with a GF Score™ of 47/100 and a GF Value™ of €3.59 (Modestly Overvalued). The stock has 8 warning signs investors should review. Among 1,368 Biotechnology companies, Macrogenics ranks better than 90.35% on this metric.

Macrogenics has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

Macrogenics has Biopharmaceutical company with some global supply chain dependencies. Manufacturing primarily in the U.S. with international sales. Moderate historical impact from tariffs on raw materials. Strong R&D focus and potential for alternative suppliers.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Macrogenics might have Highly Resilient.

Macrogenics  (FRA:M55) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Macrogenics Tariff Resilience Score Related Terms

FRA:M55 vs IMRX, TRDA, SLNCF: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Macrogenics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Macrogenics Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Macrogenics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Macrogenics's Tariff Resilience Score falls into.


FRA:M55
47GF Score
Macrogenics Inc FRA:M55
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
Macrogenics (FRA:M55) has a Tariff Resilience Score of 7 as of Jul. 09, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Macrogenics ranks #132 out of 1368 companies in the Biotechnology industry, placing it in the top 9.6%.
Is Macrogenics' Tariff Resilience Score too high?
Macrogenics' current Tariff Resilience Score is 7. The Biotechnology industry median Tariff Resilience Score is 4.00. Macrogenics' value of 7 is 75% above this industry median. Based on the distribution chart, Macrogenics ranks #132 out of 1368 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Macrogenics has a GF Score™ of 47/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Macrogenics' Tariff Resilience Score compare to IMRX and TRDA?
According to the Biotechnology industry distribution chart, Macrogenics ranks #132 out of 1368 companies for Tariff Resilience Score. This places Macrogenics in the top 10% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Macrogenics' value of 7 is 75% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,368 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Macrogenics's current Tariff Resilience Score of 7 is 75% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Macrogenics's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Macrogenics stock overvalued right now?
Based on GuruFocus' analysis, Macrogenics (FRA:M55) is currently considered Modestly Overvalued. The stock's GF Value™ is €3.59, compared to a current price of €4.12 — trading 14.8% above its estimated fair value. The current Tariff Resilience Score is 7 and 75% above the Biotechnology industry median of 4.00. Macrogenics' overall GF Score™ is 47/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Macrogenics (FRA:M55), the current Tariff Resilience Score is 7 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Macrogenics (FRA:M55) Overvalued in 2026?

Based on GuruFocus' analysis, Macrogenics stock appears to be overvalued. The current stock price of €4.12 is trading 14.8% above its estimated GF Value™ of €3.59. GuruFocus considers Macrogenics to be Modestly Overvalued.

Key valuation signals for FRA:M55:

  • Tariff Resilience Score: 7
  • GF Value™: €3.59 vs. price of €4.12 (14.8% above fair value)
  • GF Score™: 47/100 with 8 warning signs
  • Industry Position: 75% above the Biotechnology median (#132 of 1368)

No single metric tells the full story. See the FRA:M55 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Macrogenics Business Description

Other Exchanges MGNX:USA
Address 9704 Medical Center Drive, Rockville, MD, USA, 20850
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.
47GF Score

Get the complete analysis for FRA:M55

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.12
Price
€3.59
GF Value